Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Date:5/28/2008

DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave oral and poster presentations on its Cobalamin(TM) technology at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentations are entitled "Vitamin B12-Polymer Conjugates as Constructs for Targeted Tumor Delivery and for Oral Drug Delivery."

Cobalamin is Access' proprietary technology based upon the use of vitamin B12 for targeted delivery of drugs to disease sites and for oral drug delivery of drugs that otherwise have poor oral bioavailability. The presentations provide new data showing that Cobalamin-coated nanoparticles can provide a substantial lowering of blood glucose levels in an animal model of diabetes when compared with unformulated insulin given orally, and glucose-lowering effect which has much greater duration when compared with using insulin given subcutaneously. In addition, data are presented which shows that Cobalamin- targeted polymer-linked daunorubicin reduces tumor volume following intravenous administration in an animal model, providing superior efficacy when compared to polymer-daunorubicin without the targeting group, and substantially superior efficacy to daunorubicin alone.

"These new data provide strong evidence that our Cobalamin technology can be very effective in two important areas of drug development, and demonstrate that Cobalamin technology has the potential to provide a pipeline of new products in the future," commented David P. Nowotnik, PhD, Access' Senior Vice President of R&D, who presented the data at the Symposium. Dr. Nowotnik continued, "Development of an oral insulin formulation that can be moved forward rapidly into clinical development remains one of main R&D objectives." Access is also developing a Cobalamin oral formulation for human growth hormone in a research program spons
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
2. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
3. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
4. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
5. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
6. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
7. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
10. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
11. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine ... announced the business and development progress at its Jiangchuan ... the September 2014 JCM application (No. 51268) for the ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... April 26 Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... treatment of cancer, today announced that it will host a conference call ... Wednesday, May 5, 2010 , at 8:30 AM ET . , ... To participate in the conference ...
... , April 26 Cornerstone Therapeutics Inc. (Nasdaq: ... developing and commercializing significant products primarily for the respiratory and ... call at 8:00 AM ET on Tuesday, ... the quarter ended March 31, 2010 .  Management will ...
Cached Medicine Technology:Micromet to Report First Quarter 2010 Financial Results on May 5 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 3
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... 5 A failed drug launch can cost,a ... can end,up costing a company more. Leading pharmaceutical ... annual sales with a re-launch, according to a,study ... LLC., As best-in-class pharma companies have demonstrated, ...
... Remain Despite Rising Health Care Costs,Reductions in Federal ... the,continuing challenges of reductions in federal funding and ... remained committed to,providing for the needs of Pennsylvania,s ... The Governor said no Pennsylvanian currently receiving ...
... Researchers at the University of Pennsylvania School of Medicine ... associated with RNA are an important molecular guide to ... Elmer Bobst Professor of Pharmacology, and lead authors Kevin ... lab, report their findings in this week,s early online ...
... zinc supplement help protect young children from malaria" A randomized ... Journal, would suggest the answer is yes. , Jean-Bosco Ouedraogo ... (IRSS) in Bobo Dioulasso, Burkina Faso, and colleagues explain that ... normal function of the immune system, and may even play ...
... on February 14th, VICTORVILLE, Calif., Feb. 5 ... today the Victorville Senior,Valentine,s Day Luncheon. They will host ... 2:00pm at the Victorville Senior Hall., The event ... feature a sit down,meal from Carino,s Italian Grill and ...
... An unexpected finding turned out to be a clue ... St. Louis to propose a new treatment approach for ... To overcome the genetic defect in Niemann-Pick disease, the ... protein molecules through the cell,s quality control machinery. And ...
Cached Medicine News:Health News:Redefining a Product's Identity Key to a Successful Re-Launch 2Health News:Governor Rendell Says 2008-09 Budget Renews Commitment to Vulnerable Pennsylvanians 2Health News:Governor Rendell Says 2008-09 Budget Renews Commitment to Vulnerable Pennsylvanians 3Health News:Governor Rendell Says 2008-09 Budget Renews Commitment to Vulnerable Pennsylvanians 4Health News:RNA-associated introns guide nerve-cell channel production 2Health News:Supplementary approach to malaria 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: